

10/529/66  
Rec'd PCT/PTO 08 AUG 2005  
CASE PD/4-32516A

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV72461573125  
Express Mail Label Number

August 8, 2005  
Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF  
BURKHART ET AL.

INTERNATIONAL APPLICATION NO: PCT/EP2003/010700

FILED: 25 SEPTEMBER 2003

U.S. APPLICATION NO: 10/529,166

35 USC §371 DATE: Not Yet Known

FOR: TCELL MEDIATOR/MODULATOR ASSAY BASED UPON TCELL  
RESTRICTED TRANSGENIC MOUSE

**MS: Amendment**

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

This paper is supplemental to the Information Disclosure Statement filed March 24, 2005. Since it is being filed within three months of the date of entry of the national stage as set forth in 37 C.F.R. §1.491 of the international application, no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

Copies of these references are enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

  
Gregory C. Houghton  
Attorney for Applicants  
Reg. No. 47,666

Novartis  
Corporate Intellectual Property  
One Health Plaza, Building 104  
East Hanover, NJ 07936-1080  
(862) 778-2614  
Date: 8/8/05

BEST AVAILABLE COPY

## INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.  
PD/4-32  
APPLICATION NO.  
10/529,166  
APPLICANT  
BURKHART ET AL.  
FILING DATE  
Herewith

Group

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AM	0 701 607	1/10/01	EP			<input type="checkbox"/>	<input type="checkbox"/>
	AN	94/28122	12/8/94	WO			<input type="checkbox"/>	<input type="checkbox"/>
	AO	95/32285	11/30/95	WO			<input type="checkbox"/>	<input type="checkbox"/>
	AP	97/08303	3/6/97	WO			<input type="checkbox"/>	<input type="checkbox"/>
	AQ	99/16867	4/8/99	WO			<input type="checkbox"/>	<input type="checkbox"/>

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	AR	Brinkmann et al., "FTY720: Altered Lymphocyte Traffic Results in Allograft Protection", Transplantation, Vol. 72, No. 5, pp. 764-769 (2001).
	AS	Caruso et al., "Flow Cytometric Analysis of Activation Markers on Stimulated T Cells and Their Correlation with Cell Proliferation", Cytometry, Vol. 27, pp. 71-76 (1997).
	AT	Gibbons et al., "CD69 Expression After Antigenic Stimulation", Cytometry, Vol. 23, pp. 260-261 (1996).

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

BEST AVAILABLE COPY

**INFORMATION DISCLOSURE CITATION**

(Use several sheets if necessary)

ATTY. DOCKET NO.  
PD/4-32  
APPLICATION NO.  
10/529,160  
APPLICANT  
BURKHART ET AL.  
FILING DATE  
Herewith

Group

**FOREIGN PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	BA	02/00252	1/3/02	WO			<input type="checkbox"/>	<input type="checkbox"/>
	BB	02/059263	8/1/02	WO			<input type="checkbox"/>	<input type="checkbox"/>
	BC						<input type="checkbox"/>	<input type="checkbox"/>
	BD						<input type="checkbox"/>	<input type="checkbox"/>
	BE						<input type="checkbox"/>	<input type="checkbox"/>
	BF						<input type="checkbox"/>	<input type="checkbox"/>
	BG						<input type="checkbox"/>	<input type="checkbox"/>
	BH						<input type="checkbox"/>	<input type="checkbox"/>
	BI						<input type="checkbox"/>	<input type="checkbox"/>
	BJ						<input type="checkbox"/>	<input type="checkbox"/>
	BK						<input type="checkbox"/>	<input type="checkbox"/>
	BL						<input type="checkbox"/>	<input type="checkbox"/>
	BM						<input type="checkbox"/>	<input type="checkbox"/>
	BN						<input type="checkbox"/>	<input type="checkbox"/>
	BO						<input type="checkbox"/>	<input type="checkbox"/>
	BP						<input type="checkbox"/>	<input type="checkbox"/>
	BQ						<input type="checkbox"/>	<input type="checkbox"/>
	BR						<input type="checkbox"/>	<input type="checkbox"/>
	BS						<input type="checkbox"/>	<input type="checkbox"/>
	BT						<input type="checkbox"/>	<input type="checkbox"/>
	BU						<input type="checkbox"/>	<input type="checkbox"/>
	BV						<input type="checkbox"/>	<input type="checkbox"/>
	BW						<input type="checkbox"/>	<input type="checkbox"/>
	BX						<input type="checkbox"/>	<input type="checkbox"/>
	BY						<input type="checkbox"/>	<input type="checkbox"/>
	BZ						<input type="checkbox"/>	<input type="checkbox"/>

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

**BEST AVAILABLE COPY**

## INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.  
PD/4-32  
APPLICATION NO.  
10/529,166  
APPLICANT  
BURKHART ET AL.  
FILING DATE  
Herewith

Group

EXAMINER  
INITIAL

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	CA	Hari et al., "T Cell Involvement in Cutaneous Drug Eruptions", Clinical and Experimental Allergy, Vol. 31, pp. 1398-1408 (2001).
	CB	Huegin et al., "Suppression by Cyclosporin A of Murine T-Cell-Mediated Immunity Against Viruses in Vivo and in Vitro", Cellular Immunology, Vol. 90, pp. 464-473 (1985).
	CC	Huseby et al., "A Pathogenic Role for Myelin-Specific CD8 <sup>+</sup> T Cells in a Model for Multiple Sclerosis", J. Exp. Med., Vol. 194, No. 5, pp. 669-676 (2001).
	CD	Jenkins et al., "In Vivo Activation of Antigen-Specific CD4 T Cells", Annu. Rev. Immunol. Vol. 19, pp. 23-45 (2001).
	CE	Morris, "Cyclosporine, FK506 and Other Drugs in Organ Transplantation", Current Opinion in Immunology, Vol. 3, pp. 748-751 (1991).
	CF	Pinschewer et al., "FTY720 Immunosuppression Impairs Effector T Cell Peripheral Homing Without Affecting Induction, Expansion, and Memory", The Journal of Immunology, Vol. 164, pp. 5761-5770 (2000).
	CG	Rosenberg et al., "Cellular Basis of Skin Allograft Rejection: An In Vivo Model of Immune-Mediated Tissue Destruction", Annu. Rev. Immunol., Vol. 10, pp. 333-358 (1992).
	CH	Skinner et al., "Cutting Edge: In Situ Tetramer Staining of Antigen-Specific T Cells in Tissues", The Journal of Immunology, Vol. 165, pp. 613-617 (2000).
	CI	Valitutti et al., "Sustained Signaling Leading to T Cell Activation Results from Prolonged T Cell Receptor Occupancy Role of T Cell Actin Cytoskeleton", J. Exp. Med., Vol. 181, pp. 577-584 (1995).
	CJ	Wong et al., "Identification of an MHC Class I-Restricted Autoantigen in Type 1 Diabetes by Screening an Organ-Specific cDNA Library", Nature Medicine, Vol. 5, No. 9, pp. 1026-1031 (1999).
	CK	
	CL	
	CM	
	CN	

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

BEST AVAILABLE COPY